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Abstract 
Despite intensive multi-modal treatment of sarcomas, a heterogeneous group of malignant tumors 
arising from connective tissue, survival remains poor. Candidate-based targeted treatments have 
demonstrated limited clinical success, urging an unbiased and comprehensive analysis of oncogenic 
signaling networks to reveal therapeutic targets and personalized treatment strategies. Here we 
applied mass spectrometry-based phosphoproteomic profiling to the largest and most 
heterogeneous set of sarcoma cell lines characterized to date and identified novel tyrosine 
phosphorylation patterns, enhanced tyrosine kinases in specific subtypes, and potential driver 
kinases. ALK was identified as a novel driver in the Aska-SS synovial sarcoma (SS) cell line via 
expression of an ALK variant with a large extracellular domain deletion (ALKΔ2-17). Functional ALK 
dependency was confirmed in vitro and in vivo with selective inhibitors. Importantly, ALK 
immunopositivity was detected in 6/43 (14%) of SS patient specimens, one of which exhibited an ALK 
rearrangement. High PDGFRα phosphorylation also characterized SS cell lines, which was 
accompanied by enhanced MET activation in Yamato-SS cells. Although Yamato-SS cells were 
sensitive to crizotinib (ALK/MET-inhibitor) but not pazopanib (VEGFR/PDGFR-inhibitor) monotherapy 
in vitro, synergistic effects were observed upon drug combination. In vivo, both drugs were 
individually effective, with pazopanib efficacy likely attributable to reduced angiogenesis. MET or 
PDGFRα expression was detected in 58% and 84% of SS patients, respectively, with co-expression in 
56%. Consequently, our integrated approach has led to the identification of ALK and MET as 
promising therapeutic targets in SS. 
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Introduction 
Sarcomas are a heterogeneous group of malignant tumors arising in the bone or other connective 
tissue. Despite multi-modal treatment options comprising intensive polychemotherapy, radiotherapy 
and surgery, the survival of advanced sarcoma patients, with the exception of those exhibiting 
gastro-intestinal stromal tumors (GIST), has not improved substantially during the last decade (1,2), 
and side effects may affect quality of life. This emphasizes the need for novel, targeted systemic 
therapies. In recent years, the specific targeting of oncogenic signaling proteins with either small-
molecule tyrosine kinase inhibitors (TKIs) or antibodies has been the subject of numerous preclinical 
and clinical studies in sarcoma. Of these, only the multi-kinase VEGFR/PDGFR/KIT-inhibitor pazopanib 
showed an increase in progression-free survival (PFS) in a phase III study, leading to its registration in 
advanced non-adipocytic soft-tissue sarcoma (STS) after failure of standard treatment (3), and a 
phase I-II study with the PDGFRα antibody olaratumab led to an impressive but not yet understood 
overall survival improvement (4). Possible explanations for the observed limited clinical efficacy are: 
inclusion of a wide variety of sarcoma subtypes per study without incorporation of predictive 
biomarkers (2,5); and use of single inhibitors rather than combinations, since numerous studies 
demonstrate that tumors often rely on multiple signaling pathways to maintain growth and 
progression (1,2,6-8). Therefore, there is a critical need to define, at a global level, the activated 
signaling networks that drive sarcoma progression, determine how they relate to currently-defined 
sarcoma subtypes and whether they can provide a novel taxonomy for the disease, and identify 
targeted therapies and companion biomarkers for implementation of personalized treatment 
approaches.  
So far, genetic screening underpins diagnosis of different sarcoma subtypes, yet targetable driver 
mutations are rarely found in non-GIST sarcomas. While disease-specific translocations such as EWS-
ETS in Ewing sarcomas (ES) and SS18-SSX in synovial sarcomas (SS) have been demonstrated (9), the 
exact cellular functions of these fusions and their potential relationship to other oncogenic events is 
not fully understood, and targeting the translocation or associated activated pathways has not yet 
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been successful. Therefore, mutation screening to select non-GIST sarcoma patients for targeted 
therapy has not led to clinical benefit so far (1,10,11). Regarding protein biomarkers, most studies to 
date have focused on total protein expression levels, while specific screening for phosphorylation 
status or other read-outs of activation state may provide more accurate information regarding the 
pathway dependency of tumor cells and likely therapeutic benefit (2,12,13,14). To this end, we 
characterized tyrosine kinase signaling networks in a large panel of sarcoma cell lines (n=20). We 
specifically chose to include sarcoma cell lines of both the bone sarcoma and STS subtypes, and 
sarcomas occurring in adults or at pediatric/adolescent or young adult (AYA) age (Table 1). Except for 
the GIST cell line, none of the included cell lines have been phosphoprofiled before, and this is the 
first study to subject SS and angiosarcoma (AS) cell lines to phosphoproteomic analysis (6,15). This 
has enabled us to (1) characterize activated signaling networks in sarcoma (2) compare activated 
signaling networks between and within sarcoma subtypes and (3) identify driver kinases. The results 
highlight potential strategies for future personalized sarcoma treatment.  
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Materials and Methods 
 
Cell culture: ES and RMS cell lines were kindly provided by Peter Houghton, SS cell lines by Kazuyuki 
Itoh (Yamato-SS and Aska-SS), Akira Kawai (SYO-1) and Cinzia Lanzi (CME-1); AS cell lines by Mikio 
Masuzawa (MO-LAS-B and ISO-HAS-B) and the GIST cell line by Jonathan Fletcher (GIST882). All cell 
lines were obtained between 2010-2015, authenticated in our laboratory upon arrival and routinely 
tested for mycoplasma (all negative). All translocation-associated cell lines (ES, SS and aRMS) were 
authenticated in our laboratory by confirming the presence of the characteristic EWS-FLI1 (ES), SS18-
SSX1/SSX2 (SS), or PAX3-FKHR (aRMS) gene fusions as listed in Table 1 by RT-PCR. Fusion-negative 
eRMS cell lines were additionally tested for PAX3-FKHR gene fusions, which all proved to be fusion-
negative, as expected. For the GIST882 cell line, mutation analysis confirmed its known KIT mutation 
(K642E; c.1924A>G=p.Lys642Glu). AS and eRMS cell lines were tested by immunohistochemistry (IHC) 
for the presence of subtype-specific protein markers, which included expression of CD31, CD34 and 
ERG for AS cell lines, and expression of desmin and myogenin for eRMS cell lines. Authentication 
methods and results of all cell lines were reviewed by an expert sarcoma pathologist (UE Flucke, 
Radboud UMC). Cells were cultured according to their recommended conditions to approximately 
70% confluency for no longer than 25 passages in total for any experiment.   
Phosphoproteomic profiling: Prior to profiling studies, cells were harvested and homogenized in 8M 
urea lysis buffer containing phosphatase inhibitors. Lysates were sonicated and centrifuged at 14,000 
g at 4°C for 20. For each cell line, 20 mg of protein was subjected to phosphoproteomic analysis. 
First, phosphopeptides were immunoprecipitated (details: Supplementary Methods). For nanoscale 
liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS) analysis, pY-
peptides were resuspended in MS-loading buffer (0.1% formic acid and 2% ACN). Peptides were 
separated over a 30 min. gradient and MS was performed using a Thermo Fisher Scientiﬁc (San Jose, 
CA, USA) Orbitrap Plus. Up to the 10 most abundant ions (>5,000 counts) with charge states > +2 
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were sequentially isolated and further subjected to MS/MS fragmentation. MS data were analyzed 
using MaxQuant software (version 1.5.2.8.). Extracted peak lists were searched against the human 
UniProtKB/Swiss-Prot database (version 2010_10), concatenated with a proportionally sized decoy 
database for false discovery rate (FDR) as well as the reversed sequences of all entries. Protein, 
peptide, and site FDRs were controlled at a maximum of 1%. Raw pY-peptide spectral intensities 
were extracted from the ‘Evidence’ output files generated by Maxquant. These intensities were 
normalised against pY-peptide intensities for the heavy-labelled spiked-in peptide standards 
combined with GSK3B. The label-free intensity values of EFTU, MK14 and GSK3B heavy peptides in 
each cell line were averaged and a subsequent normalization factor generated. MS intensity values of 
each pY-site quantified in the dataset were divided by the appropriate normalization factor.  
Raw MaxQuant output files were subjected to the following stringent filtering criteria prior to 
inclusion in bioinformatics analysis; 1) contaminants and reversed matches were removed, ensuring 
all identifications had a FDR of <1%, 2) all non-pY-sites (serine and threonine) were removed, 3) pY-
sites were filtered for a minimum localization probability confidence of 0.75. All data was log2 
transformed prior to bioinformatics analysis. Data analyses were performed using Microsoft Office 
Excel and the bioinformatics platform Perseus (Max Planck Institute of Biochemistry, Munich) version 
1.2.0.19. For hierarchical clustering, only pY-sites with at least 10 valid values were included, 
according to standard Perseus filtering and clustering criteria. 
Pathway and network analysis: For pathway enrichment analysis, the KEGG Orthology Based 
Annotation System (KOBAS) was used (16). The hypergeometric test was applied to test statistical 
enrichment of identified KEGG and Reactome pathways, and the p-values were corrected for 
multiple comparisons using the Benjamini and Hochberg method (17). Physical interactions among 
proteins of interest were retrieved from the Protein Interaction Network Analysis (PINA) platform 
(18,19), and kinase-substrate relationships were downloaded from the PhosphoSitePlus database 
(20). The networks were generated and visualized using PINA4MS, a Cytoscape plugin for PINA. 
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Proliferation assays: The effects of small-molecule inhibitors (TAE684, crizotinib, ceritinib and 
pazopanib) on cell viability was assessed by MTT-proliferation assays as previously described 
(21,22)(details: Supplemental Table 1). 
Patient cohort: Tumor samples from 43 patients diagnosed with SS (all SS18-SSX translocation 
positive) between 1988 and 2015, were retrieved from the files of the department of Pathology of 
the Radboud University Medical Centre (Radboud UMC). Patient follow-up data was retrieved from 
the clinical records. The study was performed in accordance with the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands. Patient characteristics are listed in 
Supplemental Table 2. 
FISH: Fluorescent in situ hybridization (FISH) was performed on 2µm-thick formalin-fixed paraffin 
embedded (FFPE) tissue microarray (TMA) sections from the patient cohort described above, and an 
Aska-SS cytospin using an ALK (2p23) split-signal FISH DNA probe (Dako) as previously described (21).  
Mutation analysis: RT-PCR and sequence analysis of the RTK domain of ALK and MET was performed 
on SS cell lines as described previously (21). SS cells were additionally screened with the Cancer 
Hotspot Panel with a focus on potential PDGFRα and EGFR mutations (23). 
Sequencing Library preparation and Capture: Sequencing libraries were prepared from 1μg of Aska-
SS RNA using the KAPA Stranded RNA-Seq Library Preparation Kit (Roche). Capture was performed 
using biotinylated probes complementary to the ALK coding regions as previously described (24) with 
addition of the double Capture process according to manufacturer’s instructions. Captured libraries 
were sequenced for standard depth 126bp paired-end sequencing using the Illumina HiSeq 2500 
System v4 (Illumina). 
Sequence Analysis: Sequencing reads were deduplicated with Tally v15-065 and adaptor sequences 
removed with Cutadapt v1.8.1. Post-filtering, reads were mapped to human reference genome hg38 
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with STAR v2.4.2a and converted to UCSC genome browser tracks using the BEDTools v2.25.0 
'genomecov' command.  ALK exonic coverage was calculated from uniquely-mapping reads using the 
BEDTools coverage tool (details: Supplementary Methods). 
ALK RT-PCR: 1 μg of total RNA was reverse-transcribed to DNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). PCR was performed using the primer sequences listed in the 
Supplementary Methods. Products were gel-purified using the Gel and PCR Clean-Up System 
(Promega) and were sequenced using the PCR primers. 
Western Blot: Western Blot analysis was performed as previously described (25)(antibody details: 
Supplemental Table 3).  
PathScan analysis: PathScan signaling analysis was performed on Aska-SS cells treated with TAE684 
(25 nM), ceritinib (100 nM) or crizotinib (750 nM) and on Yamato-SS cells treated with pazopanib (10 
μM) and/or crizotinib (750 nM), all for 24h, using the human PathScan RTK signaling antibody array 
kit (Cell Signaling Technology) according to the manufacturer’s protocol. 
Deglycosylation: Cells were lysed in 2% SDS and the lysates adjusted to 0.5% SDS, 40 mM DTT and 
centrifuged at 12,000 g for 10 min at room temperature. The supernatant was then heated at 96°C 
for 10 min and 10 μg of protein treated with O-Glycosidase, Endoglycosidase H, N-glycosidase F (all 
from NEB), following manufacturer’s protocols. Tunicamycin was obtained from Sigma. Cells were 
incubated with tunicamycin (2.5-20 g/ml) for 24 h prior to preparation of cell lysates and Western 
blotting.         
Combination indices: To assess drug synergy between crizotinib and pazopanib, the combination 
index (CI) method was used (22). Cells were treated with three designated doses of crizotinib (20, 50 
and 100 nM) and pazopanib (100, 1.000 and 10.000 nM), and effects on cell viability were assessed 
by MTT assays. We next identified concentrations of each monotherapy necessary to obtain a similar 
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reduction in cell viability as observed with combined treatments. Subsequently, CI for the 
combination treatments was calculated using the formula 
CI  =  [Ca,x/ICx,a]  +  [Cb,x/ICx,b]. Ca,x and Cb,x are the concentrations of drugs A and B used in 
combination to achieve x% drug effect, ICx,a and ICx,b are concentrations for single agents to achieve 
the same effects. A CI < 1 indicates synergy of the combination therapy. A CI equal to or higher than 
1 indicates additivity or antagonism, respectively. 
Soft-agar colony forming assays: Soft-agar colony forming assays were performed as previously 
described (25).  
Mouse xenografts: Animal study protocols were performed in accordance with the guidelines of the 
Institutional Animal Welfare Committee of the Radboud University Nijmegen and Monash University. 
5x106-1x107 cells of Yamato-SS or Aska-SS cells were subcutaneously inoculated into 6–7-week-old 
female BALB/c mice (n=6-9 per group). Drug administration was initiated when tumors were 
palpable. Crizotinib, ceritinib and pazopanib were suspended in 0.5% hydroxypropylmethylcellulose 
(HPMC) + 0.5% Tween-80 to the necessary concentrations. For dose-response experiments, mice 
bearing Yamato-SS tumors were randomized into four groups receiving either crizotinib (0mg/kg, 
12.5mg/kg, 25mg/kg or 50mg/kg) once daily or pazopanib (0mg/kg, 10mg/kg, 30mg/kg or 100mg/kg) 
twice daily, both orally. Mice bearing Aska-SS tumors were treated with either vehicle or 50 mg/kg of 
crizotinib or ceritinib once daily. Tumor growth was measured twice weekly with calipers. After 28 
days of treatment, all mice were sacrificed and the resected tumors were fixed in formalin. 
Immunohistochemistry: Immunohistochemistry of MET, PDGFRα and ALK on SS patient TMAs and 
CD34 and Ki67 staining on SS tumor xenografts was performed as previously described 
(21,26)(Antibody details: Supplemental Table 3). Patient characteristics are listed in Supplemental 
Table 2. 
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Affymetrix analysis: ALK, MET and PDGFRα mRNA transcript levels were extracted from a publically-
available Affymetrix dataset (accession number GDS2736) of 105 clinical STS specimens (including 16 
SS) to compare mRNA transcript levels between sarcoma subgroups. 
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Results 
 
Phosphotyrosine profiling of human sarcoma cell lines 
Our cell line panel comprised 20 different sarcoma cell lines, including adult (AS and GIST) and 
pediatric/AYA (ES, RMS and SS) sarcomas (Table 1). Note that even though SS can occur at all ages, all 
cell lines were derived from young adult patients. Tyrosine phosphorylation patterns were 
characterized by an immunoaffinity-coupled LC-MS/MS workflow, and after application of stringent 
filter criteria (see Methods), we identified 1090 tyrosine phosphorylated peptides corresponding to 
654 proteins. Of these 1090 peptides, 334 met criteria for inclusion in subsequent hierarchical 
clustering analyses (Methods and Supplemental Table 4). Upon unsupervised hierarchical clustering 
of the different sarcoma cell lines based on their tyrosine phosphopeptide profile, the cell lines 
clustered into two major groups, being the adult sarcomas (GIST and AS) (designated Subgroup A) 
and the pediatric/AYA sarcomas (SS, RMS and ES) (Figure 1A). Since the large pediatric/AYA cluster 
split into the ES4 cell line and two smaller clusters, we have designated the latter two pediatric/AYA 
clusters Subgroups B and C, respectively (Figure 1A). Note that in this subclassification, cell lines of 
particular sarcoma subtypes do not always cluster together. The majority of the ES cell lines are split 
between Subgroups B and C. In addition, examples of RMS lines were also found in these two 
Subgroups, and this subclassification was not explained by their aRMS (translocation-positive; Table 
1) or eRMS (translocation-negative) status. However, the SS cell lines clustered together in Subgroup 
B. 
In order to identify signaling networks that exhibited differential activity across novel Subgroups A-C, 
an ANOVA-based approach was applied to identify Subgroup-enriched phosphosites, followed by 
bioinformatic determination of protein-protein interaction networks or pathways associated with 
these sites (27). Subgroup A was characterized by hyperphosphorylation of 48 phosphosites, with 
significant enrichment for the pathways associated with Fc gamma receptor (FCGR)-dependent 
phagocytosis, EPH-Ephrin signaling, adherens junctions and cytoskeletal organization (Supplemental 
on June 26, 2017. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2550 
 13
Table 5). Protein-protein interaction analysis for the proteins corresponding to these phosphosites 
revealed a network with the key hubs PTK2 (focal adhesion kinase; FAK) and ACTB (β-actin) (Figure 
1B). Other kinases present within this network were FGR, MAPK3, TYRO3, and YES1. The only 
phosphosite significantly enriched in Subgroup B versus the other two subgroups was PKP4 Y478, 
while Subgroup C was characterized by significant hypophosphorylation of 48 sites compared to 
Subgroups A and B. The protein-protein interaction network corresponding to these 
hypophosphorylated sites exhibited major hubs associated with PI3K signaling (PIK3R1, PIK3R2), and 
this approach also emphasized the decreased phosphorylation of certain kinases (PDGFRα, EPHA2 
and JAK2) in Subgroup C versus the other Subgroups (Supplemental Figure 1). 
Next, tyrosine kinases (TKs) were extracted from the original dataset, since these represent an 
important class of oncogenes and druggable targets (14). This resulted in the identification of 132 
phosphotyrosine peptides belonging to 41 TKs, including 26 receptor tyrosine kinases (RTKs) and 15 
non-receptor TKs (Supplemental Table 4). Unsupervised hierarchical clustering based on the tyrosine 
kinase-derived phosphopeptides resulted in a more complex pattern than that generated using all 
phosphopeptides, but served to highlight ALK and KIT as highly-phosphorylated ‘outliers’ in the Aska-
SS and GIST882 cell lines, respectively, that may act as drivers (Figure 1C). To facilitate comparison 
between different (R)TKs, the total tyrosine phosphorylation count was calculated per protein (see 
Methods) (Figure 2A). For RTKs, ALK, EPHA2 and KIT contributed the greatest proportion of 
phosphopeptide counts across the panel (although this reflects major contributions from individual 
cell lines for ALK and KIT, Figure 2B), whilst for non-receptor TKs, FAK, LYN, SRC and YES made the 
largest contributions (Figure 2A). Considering the phosphorylation patterns across the panel, the 
non-receptor TKs SRC/LYN/YES, FAK1 and the RTK EPHA2 were phosphorylated at high levels in the 
majority of cell lines (Figure 2B). Some tyrosine kinases exhibited enhanced phosphorylation in 
subsets of cell lines without a clear preference towards a specific sarcoma subtype (e.g. EPHB3 in 
ES7, RH18, Rh36 and Aska-SS). Certain kinases appeared to be more sarcoma subtype-specific, as 
exemplified by increased phosphorylation of DDR2 in ES cells, FGFR4 in RMS, EGFR, EPHA7 and 
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PDGFRα in SS and lastly TIE1, VEGFR2, FGR, and BMX in AS. As expected, the GIST882 cell line 
exhibited an exceptionally high level of KIT phosphorylation (Figure 2B), reflecting its KIT-driven 
phenotype and imatinib sensitivity (28). Interestingly, an extreme phosphotyrosine content was 
observed for ALK in the Aska-SS cell line, suggesting a novel and yet undescribed role for ALK as an 
oncogenic driver in SS. 
 
ALK represents a novel driver in SS 
In addition to the marked ALK tyrosine phosphorylation in Aska-SS, our MS analyses detected low 
ALK tyrosine phosphorylation on specific sites in ES2, EW8, Rh3 and Rh5. However, only Aska-SS cells 
demonstrated detectable phosphorylation on the ALK activation loop residues Y 1278, 1282 and 
1283 (29) (Supplemental Table 4). Western blotting detected expression of full-length ALK (220 kDa) 
in several sarcoma cell lines, including ES7, EW8, Rh41 and Rh3 (Supplemental Figure 2), whereas 
Aska-SS expressed two predominant anti-ALK immunoreactive bands of ~110 and 80 kDa (Figure 2C). 
Importantly, these aberrant ALK proteins in Aska-SS were detected using ALK-antibodies directed to 
pY1096, Y1507 and Y1282/1283, with highest phosphorylation levels in the 110 kDa variant (Figure 
2C). The latter observation particularly applied to activation loop phosphorylation. These data 
indicated that Aska-SS cells express truncated, activated ALK proteins, and suggested the 110 kDa 
variant represents the major driver. To determine the origin of these aberrant proteins, FISH analysis 
was undertaken, which identified heterozygous ALK breakage in Aska-SS cells (Figure 3A). RNAseq 
using an ALK Capture panel did not detect an ALK fusion partner, but instead revealed discontinuous 
coverage of ALK exons, with low expression from exon 1, absent expression from exons 2-17, and the 
majority of expression from exon 18 onwards (Figure 3B). RT-PCR confirmed the presence of mRNA 
transcripts where exon 1 (containing the usual initiation codon) is spliced to exon 18 (Figure 3C-D). 
These would encode an aberrant ALK protein lacking the extracellular region encoded by exons 2-17, 
designated ALK Δ2-17 (Figure 3E and Supplemental Figure 3) with a predicted molecular weight of 
approximately 100 kDa. Since the larger ALK immunoreactive band in Aska-SS was approximately 110 
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kDa, we determined whether the size difference between this and the predicted product was due to 
glycosylation. Treatment of Aska-SS lysate with endoglycosidase H, which targets high mannose-
containing immature N-linked carbohydrates, resulted in partial conversion of the 110 kDa band to a 
100 kDa form (Supplemental Figure 4A), while incubation with O-Glycosidase resulted in a small but 
reproducible increase in mobility. However, treatment with N-glycosidase F, which removes almost 
all types of N-linked (Asn-linked) glycosylation, resulted in complete conversion to a 100 kDa form 
consistent with the predicted size for ALK Δ2-17. This also resulted in a shift of the 80 kDa ALK band 
to approximately 70 kD. The 70 kDa form is consistent with use of initiation sites within exon 18, or 
alternatively this may represent a cleaved version of the larger variant. Treatment of cells with 
tunicamycin, an inhibitor of N-linked glycosylation, confirmed the impact of this modification on 
mobility of ALK Δ2-17 (Supplemental Figure 4B). ALK mutation analysis in the other SS cell lines 
demonstrated a previously reported ALK exon 23 deletion in Yamato-SS cells. This is known to also 
occur in RMS and ES, and has no effect on crizotinib sensitivity (20, 30, 31). 
 
To determine the functional role of ALK in SS, the effect of a panel of ALK inhibitors including the 
clinically-used compounds crizotinib (ALK/MET) and ceritinib (ALK), and the tool compound TAE684 
(ALK), on cell proliferation was determined (Figure 4A and Supplemental Table 6). Aska-SS cells were 
extremely sensitive to all three inhibitors, with IC50 values ranging between 26-46 nM. The other 
three SS cell lines exhibited markedly lower sensitivity to TAE684 and ceritinib, reflecting their lack of 
ALK activation. Yamato-SS cells were also sensitive to crizotinib, likely explained by high levels of MET 
activation, consistent with their sensitivity to the MET/VEGFR2 inhibitor foretinib (Figure 4A and 
Supplemental Figure 5). Crizotinib IC50 values were substantially higher for SYO-1 and CME-1 cells 
which exhibit undetectable or very low levels of ALK/MET tyrosine phosphorylation (Figure 2B). 
Western Blot and PathScan analysis determined that the ALK inhibitors decreased ALK 
phosphorylation in Aska-SS cells and in general, significantly reduced activation of Erk, Akt, S6RP, 
STAT3 and STAT1 (Figure 4B-C). Prolonged treatment resulted in decreased expression of Cyclin A, Rb 
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hypophosphorylation and PARP cleavage, consistent with increased cell-cycle arrest in G1 and 
enhanced apoptosis (Supplemental Figure 6). Importantly, treatment of mice bearing subcutaneous 
Aska-SS xenografts with either crizotinib or ceritinib demonstrated a remarkable dependency on ALK 
for tumor growth and maintenance, with drug treatment resulting in robust and durable tumor 
regressions (Figure 4D-E). Histopathology analyses demonstrated that these regressions were 
associated with a significant decrease in the number and size of tumor blood vessels, as well as less 
proliferative cells (Supplemental Figure 7). Overall these data demonstrate that ALK Δ2-17 activates 
multiple proliferative and survival pathways resulting in ALK addiction both in vitro and in vivo. 
 
To confirm the clinical relevance of these findings, we first interrogated a publically-available 
Affymetrix dataset of 105 clinical STS specimens (including 16 SS) and compared ALK mRNA transcript 
levels between sarcoma subgroups. This determined that ALK mRNA was significantly more highly 
expressed in SS as compared to other STS, suggesting a unique and specific role for ALK in SS versus 
other STS subtypes (Supplemental Figure 8). In addition, we assessed protein expression of ALK in 43 
primary SS patient specimens. ALK immunopositivity was observed in 6/43 (14%) of the patients 
(Figure 4F-G, Supplemental Figure 9). No significant correlation was found between ALK expression 
levels and patient outcome. The ALK-expressing samples were also evaluated by FISH. Interestingly, 
one of the six ALK-positive patients showed ALK rearrangement in 23% of the cells (100 cells 
counted; Figure 4H). This prompted us to evaluate an additional four metastatic lesions from the 
same patient. All lesions were positive for ALK expression. FISH analysis reported translocations in 
10-15.3% of cells in three of the lesions (50-150 cells counted per lesion, depending on lesion size). 
The fourth lesion showed ALK gain of up to 6 copies. These data validate our cell line-based in vitro 
and in vivo studies and highlight ALK as an important therapeutic target in a subset of SS. 
 
Kinase activation profiles and rational design of combination therapies 
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Although the phosphoproteomic analysis identified driver kinases in Aska-SS and GIST882 cell lines, 
the other sarcoma cell lines often exhibited more than one TK with high levels of activation (Figure 
1A and 2B). One way to overcome the problem of network ‘robustness’ conferred by multiple 
activated kinases is implementation of combination treatments or use of appropriate multi-kinase 
inhibitors (25). Again, we focused on the SS cell lines to further test this hypothesis. In addition to 
aberrant ALK activation in Aska-SS, these lines were characterized by high MET (in Yamato), and 
PDGFRα and EGFR phosphorylation in all of the lines (Figure 2B). No mutations were found in MET, 
PDGFRα or EGFR in any of the SS cell lines. PDGFR- or EGFR-targeted monotherapies proved 
ineffective in vitro, with at best modest growth suppression with the VEGF/PDGFR inhibitor 
pazopanib in SYO-1 cells (Figure 5A, Supplemental Figure 5 and Supplemental Table 6). Therefore, we 
determined whether simultaneous targeting of one of these kinases might enhance the observed 
sensitivity of Yamato-SS cells to the ALK/MET inhibitor crizotinib (Figure 4A). Given the robust 
expression of PDGFRα in Yamato-SS cells (Figure 5B), and the fact that pazopanib is clinically 
approved for SS treatment, this was undertaken with pazopanib. Interestingly, synergistic effects 
(CI<0.8) were observed upon combined treatment with pazopanib and crizotinib (Figure 5C), 
indicating that targeting PDGFRα is effective but only in the context of MET inhibition. Western Blot 
and PathScan signaling analysis revealed that Erk activation was sensitive to crizotinib but not 
pazopanib, and determined that combination treatment significantly reduced Akt S473 and STAT1 
Y701 phosphorylation compared to each monotherapy and control, providing potential mechanisms 
for the observed drug synergy (Figure 5D-E). Combination treatment also resulted in enhanced 
apoptosis, as indicated by the appearance of cleaved PARP at 48 h post-treatment (Supplemental 
Figure 10). Combined treatment with crizotinib and pazopanib was also significantly more effective 
than either monotherapy in soft-agar colony forming assays (Figure 5F).  
However, in mice bearing subcutaneous Yamato-SS xenografts, we observed a dose-dependent 
tumor growth retardation with each compound individually, which was more pronounced with 
crizotinib (Figure 5G-H). Crizotinib-treated tumours were characterized by significant reductions in 
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blood vessel size (mean CD34+ vessel surface for vehicle, 176.8 mm2/vessel vs. crizotinib 50mg/kg, 
129.3 mm2/vessel, p=0.0261) and tumor cell mitotic count (vehicle, 3.1±0.9 vs. crizotinib 50mg/kg, 
0.8±0.3, p=0.0057). Therefore, Yamato-SS cells exhibit a dependency on MET for tumor growth in 
vivo. In pazopanib-treated tumors, there were significantly fewer CD34+ blood vessels compared to 
controls (vehicle, 189.7/mm2 vs. pazopanib 100mg/kg, 122.2/mm2; p=0.0073; Figure 5I). This effect 
on angiogenesis, likely mediated by VEGFR inhibition, probably underpins the contrasting sensitivity 
of Yamato-SS cells to pazopanib treatment in vitro and in vivo. Overall, these data demonstrate that 
MET represents a potential therapeutic target in a subset of SS, indicate that pazopanib may also be 
of benefit for specific SS patients, and highlight the potential clinical utility of crizotinib/pazopanib 
combination treatment.  
 
MET and PDGFRα expression in SS patients 
To interrogate MET and PDGFRα expression in SS patients, we utilized publically-available Affymetrix 
gene expression data and also assayed our own cohort of clinical SS specimens by IHC. There was no 
significant difference for MET mRNA expression in SS compared to the other sarcoma histologies, but 
there was a trend for higher PDGFRα mRNA expression in SS (Supplemental Figure 8). 
Immunopositivity for MET or PDGFRα was detected in 58% (25/43) and 84% (36/43) of SS patients, 
respectively (Figure 6A-B). In 56% (24/43) of SS patients, the two proteins were co-expressed, but the 
highest scores for PDGFRα and MET were mutually exclusive. Interestingly, two of the patients 
presenting with the histological biphasic SS subtype showed a remarkable differential MET/PDGFRα 
co-expression pattern, with MET and PDGFRα expressed mutually exclusively in distinct areas of the 
tumor resembling the epithelial and spindle cell components characteristic of this subtype 
(Figure 6C). These data confirm that MET and PDGFRα represent potential therapeutic targets in SS, 
either alone or in combination. 
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Discussion 
In this study, we utilized mass-spectrometry-based phosphoproteomics to profile the largest and 
most heterogeneous set of sarcoma cell lines screened to date in order to identify perturbed 
signaling networks characteristic of existing or novel subtypes, and driver kinases that may represent 
candidate therapeutic targets. Importantly, this has identified several potential therapeutic strategies 
for specific subsets of SS patients, highlighting opportunities for personalized treatment of this 
sarcoma subtype.  
Our study identified ALK as a novel driver in the Aska-SS cell line, with exceptionally high ALK tyrosine 
phosphorylation levels similar to those of the driver kinase KIT in the imatinib-sensitive GIST882 cell 
line (28). We determined that the ALK sensitivity in Aska-SS was underpinned by expression of a 
novel truncated ALK variant lacking a significant proportion of the extracellular domain (ALK Δ2-17). 
Other activated ALK variants with extracellular domain deletions have been described in 
neuroblastoma and melanoma, where the deletions encompass regions encoded by exons 2-3, and 
all of the extracellular domain, respectively (32,33). Consequently our data add to growing evidence 
that extracellular domain deletions unleash the oncogenic potential of ALK, and represent a 
significant mechanism for ALK deregulation in human cancers, in addition to mutation, fusion and 
gene amplification/overexpression (29).  
Although all SS tumors harbor SS18-SSX fusion genes, there is a wide variety in clinical behavior and 
response to chemotherapy or targeted treatment within these tumors, emphasizing the role of 
additional factors in orchestrating SS progression (34). Our detection of ALK Δ2-17 in the Aska-SS cell 
line, and an ALK rearrangement in an ALK-immunopositive SS patient specimen, highlight ALK 
alterations as one such factor. Because the ALK aberration was detected in 1/4 SS cell lines and 1/43 
SS patients, yet all of our SS samples and cell lines harbored the characteristic SS18-SSX translocation, 
ALK is likely not associated with the characteristic SS18-SSX fusion gene. In addition, since the Aska-
SS cell line harbors SS18-SSX1, while the patient specimen contained SS18-SSX2, ALK aberrations are 
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not associated with expression of a specific SS18-SSX fusion. Since ALK activation in STS has been 
linked to the presence of metastatic lesions (35), Aska-SS is derived from a pulmonary metastatic 
lesion, and the ALK breakage-positive SS patient demonstrated breakage-positive metastases, ALK 
aberration in SS may be required for metastatic progression. However, it is clear from our 
comprehensive functional analyses in Aska-SS that ALK signaling is required for cell proliferation and 
survival in vitro, and tumor growth and maintenance in vivo. Consequently, once ALK activation 
occurs, the cancer cells can become dependent on this driver, despite the presence of a SS18-SSX 
fusion.  
We acknowledge that ALK-targeted treatment will likely not be applicable to SS tumors in general, 
but the dependency of a subset of these tumors on ALK-signaling offers great potential for 
personalized treatment within this sarcoma subtype. In this regard, ALK protein expression was 
detected in 14% of primary SS tumors and 1/6 of the ALK immunopositive-tumors exhibited ALK 
rearrangement, with the percentage of breakage-positive cells meeting diagnostic criteria for 
designation as ALK aberration-positive. The presence of a small subpopulation of SS patients 
exhibiting these characteristics is similar to non-small cell lung cancer (NSCLC), where ALK 
rearrangements are found in 2-7% of cases (36). In the latter setting, oncogenic ALK fusions are an 
established companion biomarker for crizotinib sensitivity. In addition, IC50 values for crizotinib in 
Aska-SS cells were similar to those of ALK-rearranged lymphoma cells, where ALK is an established 
clinical target (37). Consequently our work highlights ALK as an oncogenic driver and highly-
promising therapeutic target in a subset of SS. 
ALK has also been assessed as a therapeutic target in other sarcoma subtypes. A phase I dose-
escalation study of crizotinib for pediatric cancer patients, including a variety of sarcoma subtypes, 
reported enriched anti-tumor activity in patients with inflammatory myofibroblastic tumors (IMT). 
Here, the impressive response rate in this subtype was attributed to the presence of activating ALK 
aberrations. No ALK aberrations or objective responses to crizotinib were reported in other sarcoma 
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subtypes, although no SS patients were included (38). In addition to IMT, RMS have been subject to 
clinical evaluation of crizotinib efficacy based on reported ALK protein expression and gene 
amplification (NCT01548926, NCT02034981 and NCT01742286) (31). However, no objective 
responses have been reported in RMS patients (39,40). These data may reflect a failure to detect 
genomic ALK rearrangements in this subtype. Furthermore, while we could detect ALK expression in 
certain RMS cell lines, this was not accompanied by relevant levels of ALK phosphorylation, indicating 
that ALK protein overexpression in RMS may not be accompanied by receptor activation. 
Three other RTKs demonstrated enhanced activation in SS cell lines, MET in Yamato-SS, and PDGFRα 
and EGFR in all SS lines. Importantly, Yamato-SS cells were sensitive to crizotinib in vitro and in vivo, 
and over half of primary SS tumors demonstrated MET expression, highlighting MET as a potential 
therapeutic target in this sarcoma subtype. In the case of PDGFRα and EGFR, treatment of SS cells 
with pazopanib, gefitinib or erlotinib was without effect in vitro, indicating that these RTKs do not act 
as sole drivers. However, pazopanib exhibited efficacy against Yamato-SS xenografts, likely reflecting 
an additional effect on VEGFRs leading to reduced angiogenesis. The latter data are consistent with 
pazopanib monotherapy demonstrating clinical benefit in a subset of SS patients, with 49% of the 
patients having stable disease at 3 months (41). Also, in the extended phase III trial, there was a 
trend for SS patients to have superior responses on pazopanib, though this was not significant, 
possibly due to the relatively small size of this subgroup (3). Clearly, our data and recent clinical 
studies highlight the therapeutic potential for pazopanib in SS, but further work is required to 
identify biomarkers of therapeutic response that allow administration in a personalized fashion.    
Two additional aspects of our study are worthy of comment. First, we determined that a high 
proportion of clinical SS specimens co-express both MET and PDGFRα, with a subset of biphasic 
tumors exhibiting differential localization of these receptors to the epithelial and spindle cell 
components of the tumor, respectively. Although at this point we could not assess phosphorylated 
protein expression status with IHC on our clinical dataset, these data validate the presence of high 
levels of these receptors in subsets of SS patients. Second, combined treatment of Yamato-SS cells 
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with pazopanib and crizotinib demonstrated synergistic effects in vitro and in anchorage-
independent growth assays, consistent with the high expression and activation of both MET and 
PDGFRα. Although the expression of MET has been described previously in SS, explicitly in the 
epithelial part (42-43), its combination with PDGFRα expression in spindle cell parts in biphasic 
tumors is novel, as is the combination of MET and PDGFRα targeting. Consequently, our work 
highlights a potential combination therapy that could be used for SS tumors that co-express MET and 
PDGFRα, either in the same tumor region, or in a biphasic fashion. In this context, it is worth noting 
that two phase I studies in other advanced cancers are running: NCT01468922, combining the MET-
inhibitor ARQ197 with pazopanib; and NCT01548144, combining pazopanib with crizotinib. A 
preliminary case report of the latter study reported a therapeutic response and good tolerability of  
the combined treatment at the lowest doses (200mg pazopanib with 250mg crizotinib) (44), 
emphasizing its clinical potential.  
Beyond SS, the global and unbiased nature of our phosphoproteomic profiling approach enabled us 
to identify potential therapeutic targets for other sarcoma subtypes, including DDR2 in ES and FGFR4 
in RMS. In addition, molecular subclassification based on tyrosine phosphorylation patterns led to a 
novel taxonomy, with the pediatric/AYA sarcomas clustering away from adult sarcomas and 
subdivided into two subgroups. In this subclassification, cell line models of the ES and RMS sarcoma 
subtypes do not cluster together in their designated ES and RMS histological classifications, 
respectively, highlighting how knowledge of histological subtype is insufficient for assigning targeted 
treatments, and further molecular interrogation is required to design more personalized approaches. 
To this end, detailed signaling network analyses identified hyper- and hypophosphorylation 
signatures characteristic of each of the novel subgroups, revealing that the hyperphosphorylation 
pattern in Subgroup A (adult sarcomas) is built around a network with PTK2 (FAK) as a key 
component, potentially identifying FAK as a specific, and actionable vulnerability in these tumors. 
Importantly, a number of small molecule FAK tyrosine kinase inhibitors are currently undergoing pre-
clinical and clinical testing. In particular, PF-00562271, VS-4718 and VS-6063 demonstrated promising 
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clinical activity in patients with selected solid cancers, emphasizing their potential utility for sarcoma 
treatment (45, 46).  
Of note, the potential of phosphoproteomic screening of sarcomas in the clinic is underlined by 
recent studies: in a clinical (not further specified) sarcoma sample, phosphoproteomics was capable 
of detecting an ALK-rearrangement (47), as we did in the Aska-SS cell line, and this technique has also 
enabled patient stratification in RMS (48). For clinical samples, the use of reverse-phase protein 
arrays (RPPAs) or Nanostring technology may offer a practical approach for interrogating 
phosphorylation status when limited amounts of tissue are available (48). The coupling of 
phosphoproteomic approaches with other established techniques in clinical trial design and 
accompanying translational studies may therefore be of great value in design of personalized 
sarcoma treatments (49). The potential power of a phosphoproteomics approach over genomic 
analyses in SS is exemplified by the study of Ishibashi et al., in which pALK expression was detected in 
SS cases without underlying genomic aberrations (35).  
In conclusion, our study has provided detailed insights into the signaling network characteristics of 
particular sarcoma subtypes and identified potential therapeutic targets that have been validated 
using both in vitro and in vivo models and patient specimens. This work has identified protein and 
phosphoprotein markers that, following further validation, could be incorporated into pathological 
characterization of sarcomas leading to improved patient stratification for targeted treatment 
approaches.  
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Table 1.  Sarcoma cell line characteristics 
Age group Type Tissue type Cell line Translocation 
Translocation
details Subtype Prognosis 
Age at  
diagnosis Sex 
Primary 
site/specimen Metastatic site 
Refa
Pediatric 
/ AYA ES  Bone ES1 EWS-FLI1 
Exon 7/5; 
Type II   45 F Left thigh/same ? 
*
   ES2 EWS-FLI1 Exon 10/6; Type III   14 F Ilium/bone marrow Bone marrow 
* 
   ES4 EWS-FLI1 Exon 7/5; Type II   18 M Right 8
th rib Pleural cavity *
   ES7 EWS-FLI1 Exon 10/5    15 M Right fibula lesion Bone marrow, liver, femur 
*
   ES8 EWS-FLI1 Exon 7/5; Type II   10 M 
Left proximal 
humerus lesion Femur 
* 
   EW8 EWS-FLI1 Exon 7/6; Type I   17 M Abdominal mass  
* 
 RMS STS RD   eRMS Int. 7 F Pelvic mass  (1
a) 
   Rh18   eRMS Int. 2 F Perineum  (2
a)
   Rh30 PAX3-FKHR  aRMS Poor 16 M Soft tissue Bone marrow (2
a)
   Rh41 PAX3-FKHR  aRMS Poor 12 F Soft tissue Liver (2
a) 
   Rh3 PAX3-FKHR  aRMS Poor 16 M Bone Marrow Lung *
   Rh5 PAX3-FKHR  aRMS Poor 16 M Bone Marrow  *
   Rh36   eRMS  15 M Paratesticular Lymph nodes 
(2a) 
 SS STS Aska-SS SS18-SSX1  Biphasic DOD 27 M Groin Lung (3
a) 
   Yamato-SS SS18-SSX1  Biphasic DOD 30 M Thigh Lung (3
a) 
   SYO-1 SS18-SSX2  Biphasic ? 19 F Groin  (4
a)
   CME-1 SS18-SSX2  Monophasic ? 18 F Thigh  (4
a) 
Adult GIST STS GIST882    Meta    Metastatic; site unknown 
(5a)
 AS STS ISO-HAS-B   Hemangio- sarcoma  84 M 
Primary parietal-
scalp tumor 
Metastatic anterialauricular 
lesion 
(6a)
   MO-LAS-B   Lymphangio- sarcoma DOD 77 M Scalp and face 
Lung, liver, spleen, adrenal 
gland, vertebrae, rib, pleura, 
diaphragm, lymph node  
(6a) 
o
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Table 1.  Sarcoma cell line characteristics 
AYA = adolescent and young adult; STS = soft-tissue sarcoma; ES = Ewing Sarcoma; RMS = 
rhabdomyosarcoma (a = alveolar, e = embryonal); SS = synovial sarcoma; GIST = gastrointestinal 
stromal tumor; AS = angiosarcoma; Int = Intermediate; DOD = Dead of disease; ? = unknown; Meta = 
metastatic. a Provided in supplementary references list. * Personal communication with dr. Peter 
Houghton / Susan Ragsdale of the Pediatric Preclinical Testing Program (PPTP; Columbus, Ohio); St. 
Jude Childrens Hospital.  
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Figure legends 
 
Figure 1. Tyrosine phosphorylation profiling of sarcoma cell lines 
A. Unsupervised hierarchical clustering of sarcoma cell lines based on tyrosine phosphorylation 
patterns. In general, the cells clustered into two major groups: 1. adult sarcomas (GIST and AS; 
Subgroup A) and 2. pediatric/AYA sarcomas (SS, RMS and ES; further divided into Subgroups B and C). 
Color bars indicate sarcoma subgroups as described in Table 1; tyrosine phosphorylation data used to 
create this figure are provided in Supplemental Table 4, tab 2).  B. Protein-protein network analysis 
of Subgroup A revealing PTK2 (FAK) as key mediator. Red dots indicate hyperphosphorylated proteins 
found in Subgroup A only. Direct protein-protein interactions are indicated by blue lines, while 
kinase-substrate relationships are indicated by magenta lines with arrows. C. Unsupervised 
hierarchical clustering using tyrosine kinase-derived phosphopeptides. Tyrosine kinase 
phosphorylation data used to create this figure are provided in Supplemental Table 4, tab 3.  
 
Figure 2. Tyrosine phosphorylation of specific tyrosine kinases in sarcoma cell lines 
A. Contribution of individual tyrosine kinases to total phosphopeptide abundance. Each sector 
represents the sum of phosphocounts for each TK across all cell lines as a fraction of the total 
number of phosphotyrosine counts in the whole panel, and n indicates the number of cell lines in the 
panel where a given kinase was detected at any level (as detailed in Supplemental Table 4; tab 4). 
Similar colors indicate members of particular TK families. B. Phosphorylation profiles of specific TKs 
across the sarcoma cell line panel. Detailed data are provided in Supplemental Table 4, tab 4. TKs are 
divided into receptor TKs and non-receptor TKs and grouped in their respective families (14). C. ALK 
expression and phosphorylation in SS cell lines. Lysates were Western blotted with antibodies 
specific for total ALK and pALK: pY1096, pY1282/pY1283 (= activation loop) and pY1507. Red arrows 
highlight the hyperphosphorylated 110 kDa ALK variant in Aska-SS. Normal ALK has a mobility of 220 
kDa. The asterisk indicates a cross-reacting band. Actin was used as a loading control.  
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Figure 3. Characterization of the novel ALK driver in Aska-SS cells 
A. FISH analysis demonstrating ALK breakage in the Aska-SS cell line. The arrows highlight single red 
signals indicating the presence of a breakpoint, whereas the other signals comprise both green and 
red label indicating full length ALK. Image is at x630 magnification. B. Discontinuous expression of 
ALK coding exons in Aska-SS. RNAseq was undertaken following capture of transcripts corresponding 
to ALK coding regions. Note low expression of exon 1, absent expression of exons 2-17, and then high 
expression from exon 18 onwards. The black and blue bars represent the mean expression levels for 
exons 1-17 and 18-29, respectively. C. Confirmation of exon 1-exon 18 splicing in Aska-SS. RT-PCR 
was undertaken on total RNA from Aska-SS and EW8 (harboring full-length ALK). For Aska-SS, Lanes 
1, 2, 3 and 4 contain products generated from primers specific for exons 1 (forward) and 18 (reverse) 
(predicted size for ALK variant: 317 bp), exons 1 and 21 (predicted size for ALK variant: 784 bp), exon 
18 and 21 (predicted size for ALK-variant: 415 bp) and exon 1-C-terminal end of coding region 
(predicted size for ALK-variant: 2098 bp), respectively. The same reactions were undertaken for EW8, 
but only the exon 18 and 21 primers generate a detectable product as the other fragment sizes are 
too large in the context of full-length ALK. D. Confirmation of exon 1-exon 18 splicing by DNA 
sequencing. The 317 bp product generated by RT-PCR was subjected to DNA sequencing. The nature 
of other products in Panel C were also confirmed by this approach. E. Schematic representation of 
the truncated form of ALK in Aska-SS (ALK Δ2-17). The extracellular domain of full-length ALK 
comprises two MAM (meprin, A5 protein and receptor protein tyrosine phosphatase mu) domains 
(aa 264–427 and 480–626), one low-density lipoprotein class A (LDLa) motif (aa 453–471) and a 
glycine-rich region (aa 816–940) (50). Because exons 2-17 of ALK encode the aa 223–971 region, the 
deletion results in a truncated form of ALK (ALK Δ2-17) lacking these four domains. TM = 
transmembrane; PTK = protein tyrosine kinase. 
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Figure 4. Validation of ALK as a potential actionable target in SS 
A. Effect of ALK inhibitors on SS cell line proliferation in vitro. The graphs indicate dose-response 
curves of SS cell lines to crizotinib, ceritinib and TAE-684 monotherapies. Error bars represent 
standard deviations. B. Effect of crizotinib on key signaling pathways in the Aska-SS cell line. Cells 
were treated with the indicated concentrations of crizotinib for 1 h. Cell lysates were prepared and 
Western blotted with the indicated antibodies. Data are representative of duplicate experiments. C. 
Pathscan signaling pathway analysis for Aska-SS cells treated with ALK inhibitors.  Cells were treated 
with TAE684 (25 nM), ceritinib (100 nM) or crizotinib (750 nM) for 24h. All signals were significantly 
different from control (p<0.05), apart from the trends observed for ceritinib on pAkt Ser473 
(p=0.0561), TAE684 on pAkt Thr308 (p=0.0728), TAE684 on pSTAT3 Tyr705 (p=0.0636), and no 
significant difference for crizotinib on pSTAT1 Tyr701 (p=0.1563). D-E. Effect of ALK inhibitors on 
Aska-SS xenograft growth. Mice were treated with crizotinib (50 mg/kg) (D) or ceritinib (50 mg/kg) 
(E). Values are presented as mean relative tumor volume ± Standard deviation. P-values were 
assessed by Student’s t-test F. Expression of ALK in human SS. Examples of patient SS sections with 
positive (left) and negative (right) ALK expression, as determined by IHC. Images are x200 
magnification; insets are x400 magnification. G. IHC staining of ALK in Aska-SS (positive control for F). 
Image is at x200 magnification. H. FISH analysis demonstrating ALK breakage in a SS patient. The 
arrows highlight single colored signals indicating a breakpoint. Image is at x100 magnification.  
 
Figure 5. Targeting of MET and PDGFRα in in vitro and in vivo SS models  
A. Effect of pazopanib on SS cell line proliferation in vitro. The graph indicates dose-response curves 
for the different cell lines. Error bars represent standard deviations. B. Expression of total MET and 
PDGFRα RTKs in the four SS cell lines. For MET, the 145 kDa band represents mature, processed MET, 
the upper band seen in Yamato-SS is pro-MET. C. Synergism between pazopanib and crizotinib 
treatment in the Yamato-SS cell line in vitro. The x-axis and y-axis, respectively, show the relative 
concentration of pazopanib and crizotinib in synergy compared to the concentrations required in 
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monotherapy to obtain a similar effect on SS cell viability (concentration combination/concentration 
monotherapy) (details in Methods). The bold line represents a combination index of 1. Dots below, 
on or above the bold line represent synergy, additivity or antagonism, respectively. Numbers next to 
the dots indicate the concentrations of pazopanib (nM; left) and crizotinib (nM; right) used in the 
combinations. D. Effect of pazopanib and crizotinib, alone and in combination, on key signaling 
pathways in Yamato-SS cells. Cells were treated with the indicated concentrations of pazopanib and 
crizotinib for 1 h. Cell lysates were prepared and Western blotted with the indicated antibodies. Data 
are representative of duplicate experiments. E. Pathscan signaling pathway analysis for Yamato-SS 
cells treated with pazopanib and/or crizotinib. Cells were treated with crizotinib (250nM) and/or 
pazopanib (10 μM) for 24h. All signals were significantly different (p<0.05) versus control, apart from 
combination treatment on pAkt Thr308 (p=0.102) and pazopanib pStat3 Tyr705 (p=0.0825). With 
combined treatment, the reduction in pAkt Ser473 and STAT1 Tyr701 was significant compared to 
both monotherapies and control (all p<0.01; Student’s t-test). F. Effect of pazopanib and crizotinib, 
alone and in combination, on anchorage-independent growth of Yamato-SS cells. Error bars 
represent standard deviation, p-values were obtained with Student’s t-test. G. Effect of crizotinib on 
Yamato-SS xenograft growth. Mice were treated with the indicated concentrations of crizotinib. 
Values are presented as mean relative tumor volume ± SEM. *: p < 0.05; **: p < 0.01; ***: P < 0.001 
as assessed by Student’s t-test. H. Effect of pazopanib on Yamato-SS xenograft growth. Values are 
presented as in G. *: p < 0.05; **: p < 0.01 as assessed by Student’s t-test. I. Effect of pazopanib on 
angiogenesis. CD34 expression in Yamato-SS tumors from the pazopanib treatment group 
(100mg/kg) (top) and control group (bottom). Images are x100 magnification. 
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Figure 6. MET and PDGFRα expression in SS patient tumors 
A and B: Examples of patient SS sections with positive (left) and negative (right) MET and PDGFRα 
expression, respectively. C. Example of a patient with a biphasic, primary SS. Expression of MET in the 
epithelial cells (left) and PDGFRα in the mesenchymal cells (middle) is evident. General morphology is 
demonstrated by H&E staining (right). Images are x200 magnification; insets are x400 magnification. 
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